Dr. Reddy’s Laboratories Ltd. announced the recognition of the global pharmaceutical company’s largest manufacturing facility in Bachupally, Hyderabad, as part of the Global Lighthouse Network (GLN) by the World Economic Forum (WEF).
As the economy ebbs and flows, pharma and biotech companies alike are feeling the pressure to cut costs. From rapid inflation to the ever-changing regulatory landscape, many are looking for ways to reduce their burn rate.
French vaccine developer Valneva on Thursday cut its full-year revenue outlook citing lower demand for its anti-COVID shot from European Union member states.
Guidemark Health and Cyan Health have today rebranded, changing their names to Lumanity. The two agencies were acquired by Lumanity in 2021.
Abbott has stopped production of the EleCare specialty baby formula at the company’s plant in southwestern Michigan after thunderstorms and heavy rains flooded parts of the facility.
Leading healthcare venture capital firm Third Rock Ventures announced a new fund Wednesday morning, Third Rock Ventures Fund VI, providing the company with $1.1 billion to invest in new life science companies. This brings Third Rock to a total of $3.8 billion across its venture funds.
In the absence of global standards limiting toxic emissions produced by antibiotics at the point of manufacture, the pharmaceutical industry has come up with its own standard. The AMR Industry Alliance – a coalition of drugmakers, biotech, diagnostic and other companies involved in the field of antimicrobials – is adopting its own standards to ensure the responsible manufacture of antibiotics.
Bavarian Nordic raised the company’s financial guidance for 2022 for the third time in a month on Friday after receiving a large order for its monkeypox vaccine by the U.S. Biomedical Advanced Research and Development Authority (BARDA).
Richard Marritt joined Xandar Kardian, a rapidly growing technology startup utilizing ultra-wide band radar signal processing for predictive health monitoring solutions.
Contract manufacturer Emergent BioSolutions Inc. said on Monday U.S. drugmaker Johnson & Johnson (JNJ.N) had breached an agreement by failing to buy the minimum quantity of COVID-19 vaccines made by the company.